AKESOgen and Targos Form Strategic Partnership

AKESOgen and Targos form strategic partnership to enable a comprehensive biomarker service for clinical trials and molecular pathology

Kassel, Germany and Norcross, GA, USA – May 21, 2014 – Targos Molecular Pathology GmbH, a leader in clinical biomarker services and AKESOgen Inc., a leading US genomics and personalized medicine services company today announced a global commercial partnership to offer the pharmaceutical and biotech industry a wide ranging package of traditional pathology and new cutting edge molecular biomarker solutions that provides clients a wide ranging menu of biomarker offerings including IHC, FISH, molecular and cytogenomic options..

“We were attracted to AKESOgen because of their outstanding quality and service orientated approach as well as their know how in molecular genetic technologies. The unique partnership with AKESOgen will allow us to expand our comprehensive suite of services that have successfully supported the pharma market for nine years. Through this collaboration, we will be able to better serve all of our customers in the US, with the unmatched quality and value-added services that we have established over the past nine years.” said Dr. Thomas Henkel, CEO of Targos.

“Targos is an outstanding leader in Europe in molecular pathology services and teaching. We are delighted with this partnership and to support the high quality services in pathology provided by Targos as well as enable a footprint to operate out of the US.” commented Robert Boisjoli, CEO of AKESOgen.

The partnership will harness the combined strengths of both companies: AKESOgen will provide its 14,000 sq ft site and facilities near Atlanta, GA, USA as well as world class genetic and molecular expertise which will complement the undoubted quality and strengths of Targos’s companion diagnostics, pathology and biomarker capabilities.

To learn more about AKESOgen, please visit www.akesogen.com.


Contact details
George L. Kumar, PhD, MBA, Vice President of Marketing and Scientific Affairs, Targos, GmbH.

Contact details
Mark Bouzyk, PhD, Chief Scientific Officer, AKESOgen, Inc.

About Targos
Targos core service business is to provide highly standardized development and application of clinical biomarkers for the international pharmaceutical and diagnostic industry. The company has supported more than 100 international clinical trials since 1999, which have led to the successful approval of several targeted therapies and IVDs for our customers. The expert team of on-site clinical pathologists operates in a professional environment of project management, logistics, data and quality management. Targos also supports the introduction of new Companion Diagnostic assays into the market.

Targos is a fully GCP-compliant central laboratory that is inspected by the U.S. Food and Drug Administration (FDA). Targos Molecular Pathology GmbH is accredited by the College of American Pathologists (CAP). The company is also enrolled in the Clinical Laboratory Improvement Amendments (CLIA) program. www.targos-gmbh.de


About AKESOgen, Inc.
AKESOgen is a CLIA compliant integrated genomics and pharmacogenetics company providing biorepository services and high-throughput, biomarker profiling and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, methylation) for the clinical and R&D market. A private company based in Atlanta, GA, AKESOgen is a genomics contract research organization that services the academic, pharmaceutical, biotechnology, clinical testing and government sectors. The company supports a number of world class organizations including the CDC, the US Department of Veteran’s Affairs, the American Cancer Society and Kaiser Permanente. AKESOgen’s flagship clinical test is a clinical cytogenomics array for a wide ranging spectrum of cancers. AKESOgen also provides expertise in biobanking, assay development and all ancillary services in a purpose-built facility. For more information, visit www.akesogen.com.

– See more at: http://www.akesogen.com/?page=pr-2014-05-21#sthash.8RJOftGa.dpuf

Share this FacebooktwitterredditlinkedinmailFacebooktwitterredditlinkedinmail